Sphera Funds Management Ltd. Gracell Biotechnologies Inc. Call Options Transaction History

Sphera Funds Management Ltd.

  • $638 Million
  • Q1 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email